Plain-English translation of NCT03819101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large international study testing whether two inexpensive, well-known medicines— (aspirin) and (a cholesterol medication)—might help men with castrate-resistant prostate cancer live longer. Researchers will compare men who receive standard treatment alone against those who also take one or both of these medications daily. The trial involves about 1,210 men across multiple hospitals worldwide.
Castrate-resistant prostate cancer is a form that continues to grow even after hormone treatments stop working. Standard treatments help, but doctors are looking for additional options that are affordable and have few side effects. These two medications are already widely used for other health conditions, so researchers want to see if they might also benefit men facing this type of cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of four groups: standard cancer treatment alone, or standard treatment plus daily aspirin, or standard treatment plus daily cholesterol medication, or standard treatment plus both medications. You will continue your regular cancer doctor visits and treatment as planned. Researchers will follow your health over time, tracking your PSA levels and survival to see whether adding these medications makes a difference. The study is ongoing, so your commitment would be long-term participation with regular check-ins.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Czechia
France